Research To Practice | Oncology Videos

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Ibiayi Dagogo-Jack and Suresh Ramalingam on recent advances and real-world implications in lung cancer. CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Brad S Kahl and Craig Moskowitz on recent advances and real-world implications in chronic lymphocytic leukemia and lymphomas. CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Rafael Fonseca and Krina Patel on recent advances and real-world implications in multiple myeloma. CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Neeraj Agarwal and Sandy Srinivas on recent advances and real-world implications in genitourinary cancers. CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Harold Burstein and Joyce O'Shaughnessy on recent advances and real-world implications in breast cancer. CME information and select publications

Featuring a slide presentation and related discussion from Dr Joshua Sabari, including the following topics: Recent updates from ASCO 2022 in the use of EGFR- and MET-targeted therapies (0:00) Targeting HER3 in patients with advanced non-small cell lung cancer (NSCLC) with and without EGFR mutations (16:04) Recent updates in therapy for patients with EGFR exon 20 insertion mutations (21:47) DESTINY-Lung04 trial: Trastuzumab deruxtecan for patients with HER2 exon 19 or 20 mutations (2921) Using mutational status in predicting patient benefit from chemoimmunotherapy (34:51) Immune checkpoint inhibition for patients with NSCLC with EGFR mutations (38:41) Combining novel agents with immune checkpoint inhibitors for patients with NSCLC and high PD-L1 expression (47:36) CME information and select publications

Featuring an interview with Dr Joshua Sabari, including the following topics: Updates in the use of adjuvant targeted therapy for localized and metastatic non-small cell lung cancer (NSCLC); impact of the ADAURA trial (0:00) Factors in the selection of second-line therapy for patients with and without driver mutations (10:30) Role of immunotherapy for patients with driver mutations (14:26) Recent updates in the use of antibody-drug conjugates for NSCLC (17:01) Combining VEGF inhibition with other therapies for previously treated NSCLC (20:10) Factors affecting response to immunotherapy in patients with lung cancer (23:19) CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Rutika Mehta and Philip Philip on recent advances and real-world implications in gastrointestinal cancers. CME information and select publications

Featuring a slide presentation and related discussion from Dr Alexander Spira, including the following topics: Incidence and spectrum of KRAS mutations in non-small cell lung cancer (NSCLC) (0:00) Sotorasib for the treatment of NSCLC with a KRAS G12C mutation (2:06) Clinical data evaluating adagrasib for the treatment of NSCLC with a KRAS G12C mutation (9:44) Future directions in the care of patients with NSCLC with KRAS mutations (22:17) Case: A man in his early 70s with relapsed NSCLC with a G12C mutation (26:26) Case: A man in his mid 60s with newly diagnosed metastatic NSCLC with a KRAS G12C mutation (27:53) CME information and select publications

Featuring perspectives from Dr Alexander Spira, including the following topics: KRAS mutations in patients with non-small cell lung cancer (NSCLC) (0:00) KRAS small-molecule inhibitors combined with targeted therapy or immunotherapy for patients with NSCLC (3:49) KRAS small-molecule inhibitors in patients with NSCLC and brain metastases (10:52) Future role of KRAS small-molecule inhibitors as adjuvant or neoadjuvant therapy for patients with localized NSCLC (12:21) Comparing and contrasting KRAS small-molecule inhibitors for NSCLC (14:56) Future directions in targeting KRAS and other mutations (20:32) Using liquid biopsy to detect KRAS-mutated NSCLC (33:01) Common misperceptions about targeting KRAS G12C in NSCLC (35:43) CME information and select publications